Novel AKT Inhibitor Afuresertib and Bortezomib/Dexamethasone for Relapsed/Refractory MM


Novel AKT Inhibitor Afuresertib and Bortezomib/Dexamethasone for Relapsed/Refractory MM
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Rafael Fonseca, MD (2/14/14)
Voorhees PM et al. Novel AKT inhibitor afuresertib in combination with bortezomib and dexamethasone demonstrates favorable safety profile and significant clinical activity in patients with relapsed/refractory multiple myeloma. Proc ASH 2013;Abstract 283.

Dr Fonseca is Getz Family Professor of Cancer and Chair of the Department of Internal Medicine at the Mayo Clinic Arizona in Scottsdale, Arizona.